Pregnancy After Liver Transplantation: Outcomes From a Single-Center Experience
- PMID: 32655236
- PMCID: PMC7335724
- DOI: 10.1016/j.jceh.2019.10.002
Pregnancy After Liver Transplantation: Outcomes From a Single-Center Experience
Abstract
Background/objectives: Although much has been learnt regarding pregnancy after liver transplantation, data from India are scant. Hence, we evaluated the maternal and fetal outcomes of pregnancies after liver transplantation at our center.
Methods: We conducted a retrospective review of all patients who underwent liver transplantation and later conceived at our center between 2006 and 2019.
Results: Of the 750 liver transplantations performed at our center, 129 were female and 62 of them were in the childbearing age group (15-44 years). A total of seven conceptions occurred in seven patients during the study period. All the pregnancies occurred spontaneously. The median age of the patients at the time of liver transplantation and conception was 25 years (range, 24-33 years) and 29 years (range, 26-36 years), respectively. The median interval between transplantation and conception was 40 months (range, 7-48 months). All patients were on tacrolimus monotherapy. None of the patients had rejection during pregnancy despite a low median tacrolimus trough level of 2.7 ng/mL. Live birth (five cesarean and one normal) occurred in six of seven pregnancies at a median gestation age of 37.5 weeks. Mean birth weight was 3055.8 g (range, 2470-3635 g). Antenatal rubella infection and grade III intrauterine growth restriction resulting in still birth at 29 weeks occurred in one patient. The median postnatal follow-up was 25 months (range, 2-81 months). All babies and mothers were healthy.
Conclusions: Pregnancy after liver transplantation has a favorable outcome with a multidisciplinary team approach. There is a physiological reduction of tacrolimus trough levels during pregnancy for which dose augmentation is not usually required.
Keywords: ALT, alanine aminotransferase; AST, aspartate aminotransferase; IUD, intrauterine death; IUGR, intrauterine growth restriction; IgG, immunoglobulin G; US FDA, United States Food and Drug Administration; fetal; maternal; tacrolimus.
© 2019 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
The authors have none to declare.
References
-
- Casale J.P., Doligalski C.T. Pharmacologic considerations for solid organ transplant recipients who become pregnant. Pharmacotherapy. 2016;36:971–982. - PubMed
-
- Prodromidou A., Kostakis I.D., Machairas N. Pregnancy outcomes after liver transplantation: a systematic review. Transplant Proc. 2019;51:446–449. - PubMed
-
- Coscia L.A., Constantinescu S., Moritz M.J. Report from the national transplantation pregnancy registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl. 2010:65–85. - PubMed
LinkOut - more resources
Full Text Sources
